Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (703)	12/2/1998 10:08:00 PM
From: Chihcheng Hsu	Respond to of 2539

Thread: All the confusions about the labeling.... should be clarified soon. If you take a look at MTC's hourly chart, we are currently having a triangle consolidation. The direction that MTC breaks the consolidation should indicate investors' positions about yesterday's meeting. To me, the drug sector (MRK, PFE, WLA) just finishes the short term correction today and had pushed higher around today's close. If MTC won't push higher before end of Friday, then something is with MTC. I am holding my breath. CH

To: chirodoc who wrote (703)	12/3/1998 12:15:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

Curtis, you have a point, and Pfizer is the best marketer among big pharmas. So maybe MTC doesn't go up 8 points like IMNX did, or it consolidates a bit at the $42-$45 level, I don't see it going back to test the mid 30's again. It has to break out from this trading range sometime. There are some big blocks this morning at the open, one block at $44. My guess is that we would see some delayed reaction to the news in the coming weeks. We'll see. Regards. Anthony

To: chirodoc who wrote (703)	12/13/1998 8:56:00 PM
From: Anthony Wong	Read Replies (4) \| Respond to of 2539

Curtis and thread, Hermant Shah, respected independent drug analyst at HKS & Co., was interviewed at the weekend Squawk Box program of CNBC. He considered the pharmaceutical sector to be overvalued, and the biotech stocks as well, for that matter. Drug stocks he'll recommend buying now are WLA and MTC, as cheaper ways to play PFE (buying those two similar to buying PFE's marketing savvy). Said that if AHP was willing to pay some $60 for MTC, then the stock would be worth $60 to someone else; also that MTC has the lowest margin in the business, thus potentially more upside if the co. improves its efficiencies, or else it would be taken over if it continues in its old path. In essence, he said what we've all discussed previously in this thread.